5-HT2A and 5-HT2B receptor antagonists for treating stenosis of the spinal canal

Details for Australian Patent Application No. 2009331469 (hide)

Owner Pfizer Inc.

Inventors Reiter, Rudolf; Pache, Lothar

Agent Shelston IP

Pub. Number AU-A-2009331469

PCT Pub. Number WO2010/072774

Priority 08172859.4 23.12.08 EP

Filing date 22 December 2009

Wipo publication date 1 July 2010

International Classifications

A61K 31/00 (2006.01)

A61K 31/445 (2006.01) - Non-condensed piperidines, e.g. piperocaine

A61K 31/4535 (2006.01)

A61K 31/48 (2006.01) - Ergoline derivatives, e.g. lysergic acid, ergotamine

A61K 31/496 (2006.01) - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

A61P 19/08 (2006.01) Drugs for skeletal disorders

A61P 25/02 (2006.01) Drugs for disorders of the nervous system

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

21 July 2011 PCT application entered the National Phase

  PCT publication WO2010/072774 Priority application(s): WO2010/072774

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009331471-Salt forms of organic compound

2009331468-Hydrometallurgical method for the reuse of secondary zinc oxides rich in fluoride and chloride